{
  "ticker": "LLY",
  "target_date": "2025-09-11",
  "actual_date": "2025-09-11",
  "collected_at": "2025-12-08T12:16:11.308549",
  "price": {
    "open": 751.38,
    "high": 760.01,
    "low": 749.27,
    "close": 755.1709594726562,
    "volume": 2197500,
    "change_1d_pct": 0.22,
    "change_7d_pct": 2.87,
    "change_30d_pct": -0.28
  },
  "technicals": {
    "rsi_14": 69.57,
    "sma_20": 723.22,
    "sma_50": 740.58,
    "macd": 5.786,
    "macd_signal": -0.361,
    "macd_histogram": 6.147,
    "bb_upper": 766.2,
    "bb_lower": 680.24,
    "price_vs_sma20_pct": 4.42,
    "price_vs_sma50_pct": 1.97,
    "volume_ratio": 0.53
  },
  "fundamentals": {
    "market_cap": 892844048384,
    "pe_ratio": 48.798138,
    "forward_pe": 43.952778,
    "price_to_book": 37.49887,
    "price_to_sales": 15.026036,
    "profit_margin": 30.99,
    "operating_margin": 48.29,
    "roe": 96.47,
    "roa": 17.6,
    "revenue_growth": 53.9,
    "earnings_growth": 480.4,
    "debt_to_equity": 178.516,
    "current_ratio": 1.546,
    "quick_ratio": 0.724,
    "dividend_yield": 59.0,
    "fifty_two_week_high": 1111.99,
    "fifty_two_week_low": 623.78,
    "fifty_day_avg": 911.5326,
    "two_hundred_day_avg": 811.9354,
    "analyst_target": 1056.7045,
    "analyst_recommendation": "buy",
    "num_analysts": 27,
    "sector": "Healthcare",
    "industry": "Drug Manufacturers - General",
    "pct_from_52w_high": -10.43,
    "pct_from_52w_low": 59.67
  },
  "macro": {
    "spy": {
      "price": 655.81,
      "change_1d_pct": 0.83,
      "change_7d_pct": 2.16
    },
    "vix": {
      "level": 14.71,
      "signal": "LOW_FEAR"
    },
    "treasury_10y": {
      "yield_pct": 4.01
    },
    "dollar_index": {
      "level": 97.54
    },
    "gold": {
      "price": 3636.9
    },
    "regime": "BULL_LOW_VOL"
  },
  "news": [
    {
      "headline": "Eli Lilly loses appeal of $183.7 million Medicaid fraud award",
      "source": "Yahoo",
      "datetime": 1757615360,
      "summary": "A federal appeals court on Thursday rejected Eli Lilly's appeal of an $183.7 million judgment won by a whistleblowing lawyer and pharmacist who accused the drugmaker of defrauding Medicaid.  The 7th U.S. Circuit Court of Appeals in Chicago said a federal jury reasonably found that Lilly knowingly co",
      "url": "https://finnhub.io/api/news?id=098e0a252c5e5b3f3622f892b771acfc1e2c086bc4aa5edaea8f6786ef169ddf"
    },
    {
      "headline": "Where Does VKTX Stock Stand After the Obesity Pill Setback?",
      "source": "Yahoo",
      "datetime": 1757602920,
      "summary": "Viking Therapeutics faces pressure after mixed oral obesity pill trial results, raising safety concerns but still meeting key study goals.",
      "url": "https://finnhub.io/api/news?id=f50b38c6e140ba65f54f1225b6b9eec53082d91d1fc044e6c2fd93d91f301809"
    },
    {
      "headline": "Lilly to participate in Bernstein's 2nd Annual Healthcare Forum",
      "source": "Yahoo",
      "datetime": 1757602800,
      "summary": "Eli Lilly and Company (NYSE: LLY) will participate in the Bernstein's 2nd Annual Healthcare Forum on September 25, 2025. Lucas Montarce, executive vice president and chief financial officer, will take part in a fireside chat at 8 a.m., Eastern time.",
      "url": "https://finnhub.io/api/news?id=86a15c1891a33de104fca7bc3a1c9d2fa45325c47aeaff498ea165e3fc7a9c77"
    },
    {
      "headline": "Novo Nordisk tells staff to return to office full-time amid CEO's revival effort",
      "source": "Yahoo",
      "datetime": 1757601646,
      "summary": "Wegovy-maker Novo Nordisk said on Thursday it had told all its staff to return to the office as the drugmaker's new CEO tries to accelerate decision-making and improve its commercial execution amid intense competition in the obesity drug market.  Amazon and others already asked staff to return to th",
      "url": "https://finnhub.io/api/news?id=91bb438d28797fcf3f9d19b5bee113891856aeb3de0cf1a360d3b30d592e0966"
    },
    {
      "headline": "Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors",
      "source": "Yahoo",
      "datetime": 1757600100,
      "summary": "\u2013 Dr. Chang led XOLAIR\u00ae from invention through FDA approval and commercialization, exceeding $5 billion in sales so far \u2013 Los Angeles, CA, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (\u201cCompany\u201d, \u201cWe\u201d or \u201cUs\u201d), a clinical-stage biopharmaceutical company developing cell therapies for AL A",
      "url": "https://finnhub.io/api/news?id=3d3b600ae9c85d08d9d538b9dc9121101c6b98447429130fa460635edb975cef"
    }
  ],
  "news_count": 5,
  "sec_filings": [
    {
      "form": "4",
      "date": "2025-09-08",
      "description": "xslF345X05/wk-form4_1757362781.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000238/xslF345X05/wk-form4_1757362781.xml"
    },
    {
      "form": "4",
      "date": "2025-08-28",
      "description": "xslF345X05/wk-form4_1756412129.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000236/xslF345X05/wk-form4_1756412129.xml"
    },
    {
      "form": "4",
      "date": "2025-08-28",
      "description": "xslF345X05/wk-form4_1756412046.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000234/xslF345X05/wk-form4_1756412046.xml"
    },
    {
      "form": "8-K",
      "date": "2025-08-20",
      "description": "d929636d8k.htm",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000119312525184093/d929636d8k.htm"
    },
    {
      "form": "4",
      "date": "2025-08-19",
      "description": "xslF345X05/wk-form4_1755634987.xml",
      "url": "https://www.sec.gov/Archives/edgar/data/59478/000005947825000232/xslF345X05/wk-form4_1755634987.xml"
    }
  ],
  "sec_filings_count": 5,
  "data_quality": {
    "has_price": true,
    "has_technicals": true,
    "has_fundamentals": true,
    "has_macro": true,
    "has_news": true,
    "has_sec_filings": true
  }
}